Palliative and supportive therapy in cases of renal cell carcinoma
作者： M. Kurosch , S. Buse , J. Bedke , N. Wagener , A. Haferkamp
DOI: 10.1007/S00120-006-1268-3
关键词:
摘要: Bereits bei Diagnosestellung liegt ca. 25–30% aller Patienten mit einem Nierenzellkarzinom eine Metastasierung vor. Bei weiteren 20–30% der Patienten, die sich einer radikalen Nephrektomie kompletter Tumorentfernung unterzogen haben, kommt es zu Progress. In diesem Ubersichtsartikel wird auf aktuellen therapeutischen Optionen beim metastasierten eingegangen. Dazu zahlen im Einzelnen operativen Therapieoptionen wie zytoreduktive Tumornephrektomie oder Metastasenchirurgie aber auch Embolisation, medikamentose Therapieansatze (Chemotherapie, Immuntherapie und „targeted therapy“) sowie supportive Schmerztherapie.
springer.com
sci-hub.se 参考文章(59)
H. J. Hansmann, P. Hallscheidt, K. Aretz, G. W. Kauffmann, G. M. Richter, Renal tumor embolization Radiologe. ,vol. 32, pp. 127- 131 ,(1992) , 10.1007/S001170050576
Amato Rj, Chemotherapy for renal cell carcinoma. Seminars in Oncology. ,vol. 27, pp. 177- 186 ,(2000)
Chris Coppin, Franz Porzsolt, Michael Autenrieth, Julia Kumpf, Andrew Coldman, Timothy Wilt, Immunotherapy for advanced renal cell cancer Cochrane Database of Systematic Reviews. ,vol. 2015, ,(2015) , 10.1002/14651858.CD001425.PUB2
R. M. Bukowski, C. M. Baum, S. T. Kim, R. J. Motzer, T. E. Hutson, R. A. Figlin, M. D. Michaelson, P. Tomczak, S. Oudard, O. Rixe, Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) ASCO Meeting Abstracts. ,vol. 24, ,(2006)
R. J. Motzer, B. I. Rini, M. D. Michaelson, B. G. Redman, G. R. Hudes, G. Wilding, R. M. Bukowski, D. J. George, S. T. Kim, C. M. Baum, Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) Journal of Clinical Oncology. ,vol. 23, pp. 4508- 4508 ,(2005) , 10.1200/JCO.2005.23.16_SUPPL.4508
J P Kavolius, D P Mastorakos, C Pavlovich, P Russo, M E Burt, M S Brady, Resection of metastatic renal cell carcinoma. Journal of Clinical Oncology. ,vol. 16, pp. 2261- 2266 ,(1998) , 10.1200/JCO.1998.16.6.2261
L M Minasian, R J Motzer, L Gluck, M Mazumdar, V Vlamis, S E Krown, Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. Journal of Clinical Oncology. ,vol. 11, pp. 1368- 1375 ,(1993) , 10.1200/JCO.1993.11.7.1368
W.K. Lau, H. Zincke, C.M. Lohse, J.C. Cheville, A.L. Weaver, M.L. Blute, Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review BJU International. ,vol. 91, pp. 775- 779 ,(2003) , 10.1046/J.1464-410X.2003.04237.X
I. Bleumer, E. Oosterwijk, J.C. Oosterwijk-Wakka, M.C.W. Völler, S. Melchior, S.O. Warnaar, C. Mala, J. Beck, P.F.A. Mulders, A Clinical Trial With Chimeric Monoclonal Antibody WX-G250 and Low Dose Interleukin-2 Pulsing Scheme for Advanced Renal Cell Carcinoma The Journal of Urology. ,vol. 175, pp. 57- 62 ,(2006) , 10.1016/S0022-5347(05)00040-6
C.M.L. van Herpen, P.H.M. De Mulder, Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Critical Reviews in Oncology Hematology. ,vol. 41, pp. 327- 334 ,(2002) , 10.1016/S1040-8428(01)00173-1